Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC By Ogkologos - August 20, 2025 535 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KRYSTAL-12 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Patients with Breast, Colorectal, and Pancreatic Cancers With ATM, CHEK2, or... March 18, 2025 Some Women Avoid Breast Cancer Screening After False-Positive Mammogram Results October 4, 2024 FDA Grants Regular Approval to Pembrolizumab and Lenvatinib for Advanced Endometrial... July 23, 2021 First Mature Estimation of Median OS for Selpercatinib in Patients with... March 12, 2025 Load more HOT NEWS Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with... FDA Grants Accelerated Approval to Elranatamab-bcmm for Multiple Myeloma Νέα για τον καρκίνο του προστάτη EMA Recommends Extension of Indications for Durvalumab in the Management of...
